Prescription Required
Formulation: Tablet
Prescription Required
Formulation: Tablet
(Generic Alternative)
Select the prescribed dosage
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Epivir HBV (lamivudine) is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection in adults and children aged 2 years and older.
Hepatitis B is a viral infection that affects the liver. It occurs when the hepatitis B virus enters liver cells and begins multiplying, causing inflammation and potentially damaging liver tissue.
When hepatitis B infection lasts longer than six months, it is considered chronic. Chronic hepatitis B can cause ongoing liver inflammation and, over time, may lead to serious complications such as liver scarring (fibrosis), cirrhosis, liver failure, or liver cancer.
Epivir HBV contains lamivudine, an antiviral medication that helps prevent hepatitis B from multiplying inside liver cells.
By reducing the amount of hepatitis B virus in your body, Epivir HBV can help decrease liver inflammation, improve certain liver function test results, and reduce ongoing damage to your liver.
Although Epivir HBV can help control chronic hepatitis B, it does not cure the infection or completely eliminate the virus from your body.
Your healthcare provider will determine whether Epivir HBV is appropriate based on your hepatitis B viral load, liver function, medical history, kidney function, and previous antiviral treatments.
Epivir HBV is used to treat chronic hepatitis B infection in patients who have evidence of ongoing viral replication and active liver inflammation.
The hepatitis B virus infects liver cells and uses their machinery to produce new copies of itself. As the virus continues multiplying, the immune system may respond by attacking infected liver cells, leading to inflammation and liver damage.
Some people with chronic hepatitis B experience symptoms such as fatigue, loss of appetite, nausea, or discomfort in the upper right side of their abdomen.
However, many people have no noticeable symptoms, even when the infection is causing liver inflammation.
Without appropriate monitoring and treatment, chronic hepatitis B may gradually damage the liver and increase the risk of serious complications.
Epivir HBV helps manage chronic hepatitis B in several important ways:
Epivir HBV is not recommended as a first-choice treatment for most people with chronic hepatitis B because the virus can develop resistance to lamivudine.
Your healthcare provider may recommend other antiviral medications, such as tenofovir or entecavir, which generally have a lower risk of developing resistance.
Epivir HBV may still be considered when alternative antiviral treatments are not available or appropriate for your circumstances.Â
Epivir HBV contains lamivudine, an antiviral medication that belongs to a class of drugs called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
These medications interfere with the process viruses use to make copies of their genetic material.
The hepatitis B virus relies on an enzyme called HBV DNA polymerase, which also has reverse transcriptase activity, to reproduce inside infected liver cells.
This enzyme plays an important role in converting viral genetic material into new hepatitis B DNA.
Lamivudine interferes with this process, making it more difficult for the virus to produce new copies of itself.
Blocks Hepatitis B Viral DNA Production
After you take Epivir HBV, lamivudine enters your body’s cells and is converted into its active form, lamivudine triphosphate.
This active form interferes with the hepatitis B virus’s DNA polymerase enzyme.
During viral replication, the enzyme normally builds new strands of viral DNA.
Lamivudine triphosphate resembles one of the building blocks used to create DNA. When it becomes incorporated into the developing viral DNA chain, it prevents the chain from being completed.
This process is called DNA chain termination.
By interrupting viral DNA production, lamivudine helps prevent hepatitis B from producing new infectious virus particles.
Reduces Hepatitis B Viral Replication
When hepatitis B cannot efficiently reproduce, the amount of virus circulating in your bloodstream may decrease.
This reduction is measured through a blood test called an HBV DNA test, which determines how much hepatitis B viral genetic material is present in your blood.
A lower HBV DNA level generally indicates that antiviral treatment is helping suppress the virus.
Reducing viral replication can help limit ongoing inflammation and damage to liver cells.
However, lamivudine does not completely remove hepatitis B from infected liver cells. The virus can persist even when blood tests show very low levels of viral activity.
This is why continued treatment and regular monitoring may be necessary.
Helps Reduce Liver Inflammation
Chronic hepatitis B can cause persistent inflammation as your immune system responds to infected liver cells.
Over time, ongoing inflammation may contribute to liver scarring and reduced liver function.
By lowering the amount of hepatitis B virus in your body, Epivir HBV can help decrease the activity driving this inflammation.
As viral replication decreases, liver enzyme levels may improve.
Your healthcare provider may monitor ALT and aspartate aminotransferase (AST), two enzymes that can increase when liver cells are damaged.
An improvement in these blood tests may indicate that liver inflammation is decreasing.
However, normal liver enzyme levels do not always mean the infection is completely controlled, so additional testing remains important.
When Epivir HBV successfully suppresses hepatitis B replication, it may help improve several aspects of liver health.
The main benefits include lowering HBV DNA levels, decreasing liver inflammation, improving liver enzyme results, and reducing ongoing injury to liver cells.
In some patients, treatment may also support changes in hepatitis B blood markers, such as hepatitis B e antigen (HBeAg). These changes can help your healthcare provider evaluate how the infection is responding to treatment.
However, treatment results vary depending on your viral load, liver condition, previous treatments, and whether the virus develops resistance.
Epivir HBV does not guarantee that liver damage will stop progressing, and regular screening for liver complications may still be necessary.
Epivir HBV begins interfering with hepatitis B viral replication after treatment starts, but improvements in your laboratory results may take several weeks or months to become noticeable.
Your healthcare provider will monitor how well the medication is working through regular blood tests.
These tests may include HBV DNA levels, liver enzymes, and other hepatitis B markers.
Some people experience a substantial reduction in viral load during treatment, while others may respond more slowly.
The length of treatment depends on your hepatitis B status, liver health, laboratory results, and the risk of developing antiviral resistance.
Continue taking Epivir HBV exactly as prescribed, even if you feel well or your liver enzyme levels improve.
Do not stop taking Epivir HBV without consulting your healthcare provider. Stopping hepatitis B treatment can cause the virus to become more active again and may lead to a serious worsening of liver inflammation.
Epivir HBV is available in oral tablet and liquid formulations. The usual adult dosage is 100 mg once daily, although your healthcare provider may recommend an adjusted dosage if you have reduced kidney function.
The medication is also approved for certain children aged 2 years and older, with pediatric doses determined by body weight.Â
Before starting treatment, your healthcare provider should assess your hepatitis B infection and recommend HIV testing.
This is important because lamivudine is also used to treat HIV, but the dose of lamivudine in Epivir HBV is not appropriate for treating HIV infection.
Using Epivir HBV alone in someone who also has HIV may allow HIV to develop resistance to lamivudine, making future HIV treatment more difficult.
Tell your healthcare provider if you have HIV, kidney disease, other liver conditions, or have previously taken hepatitis B medications.
Regular laboratory monitoring is important throughout treatment to evaluate viral suppression, liver function, and signs of antiviral resistance.
Epivir HBV helps manage chronic hepatitis B by interfering with viral DNA production, reducing viral replication, and decreasing liver inflammation. Although it does not cure hepatitis B, appropriate antiviral treatment and ongoing medical monitoring can help protect your liver and reduce the risk of complications.
Epivir HBV is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection. It works by preventing the hepatitis B virus from multiplying, helping reduce the amount of virus in your body and protecting your liver from ongoing inflammation and damage.
Epivir HBV is available as an oral tablet and an oral solution. The medication is usually taken once daily, with or without food, or as directed by your healthcare provider.
The recommended dosage depends on your age, body weight, kidney function, and overall medical condition.
Although lamivudine is also used to treat HIV infection, the dosage and formulation prescribed for HIV differ from those used for hepatitis B. Epivir HBV should not be used as the only treatment for someone who has both HIV and hepatitis B.
Always follow the instructions on your prescription label. Do not increase, decrease, or change your dosage without consulting your healthcare provider.
The usual recommended dosage of Epivir HBV for adults with chronic hepatitis B is 100 mg once daily, provided they have adequate kidney function.
For children aged 2 to 17 years, the dosage is generally determined by body weight, up to a maximum of 100 mg daily.
Your healthcare provider may recommend a lower dosage if you have reduced kidney function because lamivudine is primarily removed from your body through the kidneys.
Epivir HBV can be taken with or without meals, making it easier to incorporate into your daily routine.
Take your medication at approximately the same time every day to help maintain consistent drug levels in your body.
Do not take additional tablets or use a higher dose in an attempt to improve treatment results.
Follow these steps to take Epivir HBV safely and correctly:
Take Epivir HBV at the Same Time Every Day
Taking Epivir HBV at approximately the same time each day helps maintain consistent medication levels in your body.
Lamivudine works by interfering with hepatitis B viral replication. Taking the medication regularly helps keep the virus suppressed.
If you frequently miss doses, the amount of hepatitis B virus in your body may increase, potentially leading to worsening liver inflammation.
Inconsistent treatment can also contribute to the development of antiviral resistance, making lamivudine less effective.
Consider setting a daily phone reminder or using a medication organizer to help you maintain your treatment schedule.
Take the Medication With or Without Food
Epivir HBV can be taken with or without food.
You do not need to follow a special meal schedule when taking the medication unless your healthcare provider recommends otherwise.
If you experience mild nausea or stomach discomfort, taking your dose with a meal or snack may help.
Try to take the medication consistently each day, regardless of whether you choose to take it with food.
Do Not Change Your Dosage
Do not increase, decrease, or change your prescribed dose of Epivir HBV without medical advice.
Taking more medication than prescribed may increase your risk of unwanted side effects without providing additional antiviral benefits.
Taking less medication than prescribed may reduce the effectiveness of treatment and allow hepatitis B to multiply.
If you have kidney disease or your kidney function changes during treatment, your healthcare provider may need to adjust your dosage.
Always discuss concerns about your medication with your healthcare provider before making changes.
Continue Taking Epivir HBV Even if You Feel Well
Chronic hepatitis B often causes few or no noticeable symptoms, even when the virus is active and affecting your liver.
As a result, you may feel healthy while still having an ongoing hepatitis B infection.
Epivir HBV helps reduce viral replication, but it does not completely eliminate the virus from your body.
Continue taking Epivir HBV exactly as prescribed, even if your symptoms improve or your blood tests show a lower viral load.
Stopping treatment without medical supervision may allow hepatitis B to become more active again and cause a serious worsening of liver inflammation.
Your healthcare provider will determine when, or whether, it is appropriate to discontinue treatment based on your laboratory results and overall liver health.
If you forget to take Epivir HBV, take the missed dose as soon as you remember.
However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule.
Do not take two doses at the same time or double your next dose to make up for a missed tablet.
Missing doses may allow hepatitis B to multiply again, potentially increasing your viral load and causing additional liver inflammation.
Repeated missed doses may also increase the risk of the hepatitis B virus developing resistance to lamivudine.
If you frequently forget doses or miss several doses in a row, contact your healthcare provider or pharmacist for advice on how to resume treatment safely.
Epivir HBV helps control chronic hepatitis B by reducing viral replication, but it does not cure the infection.
Even if your viral load decreases and your liver function tests improve, hepatitis B may remain present in your liver.
Stopping treatment can allow the virus to begin multiplying again, potentially causing a sudden worsening of liver inflammation.
This is sometimes called a hepatitis B flare or acute exacerbation of hepatitis B.
In some cases, a hepatitis B flare can cause serious liver damage, particularly in people who already have advanced liver disease.
Never stop taking Epivir HBV without consulting your healthcare provider.
If treatment needs to be discontinued, your healthcare provider may recommend regular blood tests and close monitoring of your liver function for several months afterward.
Try to refill your prescription before your current supply runs out.
Interrupting treatment because you have no medication available may allow hepatitis B to become more active again.
Check your medication supply regularly and arrange refills in advance, particularly before travelling or during holidays.
If you are running low or have already run out of Epivir HBV, contact your pharmacist or healthcare provider as soon as possible.
Do not take someone else’s medication or substitute a different lamivudine product without medical advice.
Regular medical appointments and blood tests are important while taking Epivir HBV.
Your healthcare provider will monitor your response to treatment and determine whether the medication continues to control your hepatitis B infection effectively.
Monitoring may include:
Your healthcare provider will determine how frequently these tests are needed based on your medical history and treatment response.
Lamivudine is used to treat both hepatitis B and HIV, but the two conditions require different treatment regimens.
Epivir HBV is formulated and dosed for chronic hepatitis B infection, while Epivir for HIV contains lamivudine at doses appropriate for HIV treatment.
If you have both HIV and hepatitis B, Epivir HBV alone is not an appropriate treatment because its lower lamivudine dose may allow HIV to develop drug resistance.
Your healthcare provider should assess your HIV status before starting Epivir HBV and recommend an appropriate treatment regimen if both infections are present.
Do not switch between Epivir HBV and other lamivudine products without consulting your healthcare provider.Â
Contact your healthcare provider if you frequently miss doses, have difficulty taking your medication, or experience unusual symptoms while using Epivir HBV.
Seek prompt medical advice if you develop worsening fatigue, persistent nausea, dark urine, yellowing of your skin or eyes, or abdominal pain. These symptoms may indicate liver problems requiring medical evaluation.
If you are considering stopping treatment or changing your dosage, discuss your concerns with your healthcare provider first.
Always take Epivir HBV exactly as prescribed. Taking your medication consistently, avoiding treatment interruptions, and attending regular medical appointments can help control chronic hepatitis B while reducing the risk of liver complications.
Epivir HBV (lamivudine) is available in the following forms and strength:
Before taking Epivir HBV, tell your healthcare provider about any medical conditions, allergies, or medications you are taking.
Epivir HBV is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection. It works by preventing the hepatitis B virus from multiplying, helping reduce viral activity and protect your liver from ongoing inflammation and damage.
Although Epivir HBV can help control chronic hepatitis B, it may cause serious side effects in some people. Certain precautions are especially important if you have liver disease, kidney disease, HIV infection, or a history of other medical conditions.
Your healthcare provider may recommend regular blood tests and medical appointments to monitor your liver function, kidney health, and response to treatment.
Do not stop taking Epivir HBV without consulting your healthcare provider. Suddenly discontinuing treatment can cause hepatitis B to become more active and may lead to serious liver complications.
Stopping Epivir HBV may cause a serious worsening of hepatitis B infection, sometimes called an acute exacerbation of hepatitis B or a hepatitis B flare.
Epivir HBV works by reducing the amount of hepatitis B virus in your body. However, the medication does not completely eliminate the virus from your liver.
If treatment is stopped, hepatitis B may begin multiplying again, causing your viral load to increase and triggering renewed liver inflammation.
In some cases, this inflammation can become severe and lead to significant liver damage.
The risk is particularly concerning in people who already have advanced liver disease, although hepatitis B flare-ups can occur in other patients as well.
Warning signs of worsening hepatitis B may include:
Your healthcare provider will determine whether treatment should be continued, changed, or discontinued based on your viral load, liver function, and overall health.
If Epivir HBV must be stopped, close medical monitoring is necessary for at least several months afterward.
This monitoring may include liver enzyme tests and HBV DNA testing to identify signs of renewed viral activity.
Never stop taking Epivir HBV or change your dosage without medical advice. Contact your healthcare provider promptly if you develop symptoms that may indicate worsening liver disease.Â
Epivir HBV may rarely cause a serious condition called lactic acidosis, which occurs when excessive amounts of lactic acid build up in your bloodstream.
Lactic acid is naturally produced by your body during normal metabolism. However, certain medications can interfere with how your cells produce and use energy, allowing lactic acid to accumulate.
Lamivudine belongs to a class of medications called nucleoside analogues, which have been associated with lactic acidosis in rare cases.
Although uncommon, lactic acidosis can become life-threatening without prompt medical treatment.
Possible warning signs include:
The risk of lactic acidosis may be higher in people with certain risk factors, including severe obesity, underlying liver disease, or prolonged exposure to nucleoside analogue medications.
However, this condition can also occur in people without known risk factors.
Seek emergency medical attention immediately if you develop symptoms that may indicate lactic acidosis.
Your healthcare provider will determine whether Epivir HBV needs to be interrupted and whether additional medical treatment is necessary.
Epivir HBV and other nucleoside analogue medications have rarely been associated with severe liver enlargement, known as hepatomegaly, and the accumulation of fat in liver cells, known as hepatic steatosis.
These conditions can interfere with normal liver function and may occur alongside lactic acidosis.
Your liver performs several essential functions, including processing nutrients, filtering harmful substances, and producing proteins that help your blood clot.
When the liver becomes enlarged or damaged, these functions may be affected.
Possible symptoms include persistent nausea, loss of appetite, abdominal pain, unusual tiredness, dark urine, or yellowing of your skin or eyes.
In severe cases, liver complications may become life-threatening.
Tell your healthcare provider if you have existing liver disease, a history of fatty liver, or other conditions affecting liver health.
Regular blood tests may be recommended to monitor liver function during treatment.
Contact your healthcare provider immediately if you develop symptoms of liver injury. Severe symptoms, particularly those accompanied by confusion, fainting, or difficulty breathing, require emergency medical attention.
Epivir HBV contains lamivudine, an antiviral medication that is active against both hepatitis B virus and human immunodeficiency virus type 1 (HIV-1).
However, Epivir HBV is not approved for treating HIV-1 infection because its lamivudine dosage is lower than the dosage used in HIV treatment.
The usual adult dose of Epivir HBV is 100 mg once daily, while lamivudine-containing HIV treatment regimens use different doses and combinations of antiretroviral medications.
If you have both HIV and hepatitis B, taking Epivir HBV alone may allow HIV to develop resistance to lamivudine.
Drug resistance occurs when a virus develops changes that allow it to continue multiplying despite exposure to medication.
Once resistance develops, lamivudine and certain related HIV medications may become less effective.
For this reason, your healthcare provider should recommend HIV testing before you begin Epivir HBV and may repeat testing during treatment when appropriate.
If you have both HIV and hepatitis B, your healthcare provider will recommend an antiretroviral treatment regimen that appropriately addresses both infections.
Do not switch between Epivir HBV and other lamivudine-containing medications without medical supervision.
Tell your healthcare provider if you have HIV, may have been exposed to HIV, or are uncertain about your HIV status before starting Epivir HBV.Â
Hepatitis B may develop resistance to lamivudine during treatment, especially when the medication is used for an extended period.
When resistance develops, the hepatitis B virus may begin multiplying again even though you continue taking Epivir HBV as prescribed.
This can cause your HBV DNA levels to increase and may lead to worsening liver inflammation.
Lamivudine has a relatively low barrier to resistance compared with certain newer hepatitis B medications.
For this reason, Epivir HBV is generally not considered a preferred first-line treatment for most people with chronic hepatitis B when other effective antiviral medications are available.
Your healthcare provider may recommend regular HBV DNA testing and liver enzyme monitoring to determine whether treatment continues to work effectively.
If the virus becomes resistant to lamivudine, your healthcare provider may recommend switching to another antiviral medication.
Do not increase your dosage or stop treatment on your own if your hepatitis B laboratory results change.
Tell your healthcare provider or pharmacist if you take any medications containing sorbitol.
Sorbitol is a sugar alcohol commonly used as a sweetener or inactive ingredient in certain liquid medications, including some cough syrups, oral solutions, and laxatives.
Research involving lamivudine has shown that taking it with sorbitol may reduce the amount of lamivudine absorbed into the bloodstream.
This interaction is particularly relevant when lamivudine and sorbitol-containing oral products are taken together.
Reduced lamivudine exposure could potentially affect how effectively the medication suppresses viral replication.
Whenever possible, avoid regularly combining lamivudine with sorbitol-containing medications unless your healthcare provider determines that the combination is appropriate.
Before using a new liquid medication, check the ingredient list or ask your pharmacist whether it contains sorbitol.
Do not stop a prescribed medication without first discussing possible alternatives with your healthcare provider.
People with chronic hepatitis B may develop serious liver complications if the infection becomes more active or liver inflammation worsens.
One particularly serious complication is hepatic decompensation, which occurs when the liver becomes too damaged to perform its normal functions effectively.
This risk may be greater in people who already have cirrhosis or advanced liver disease.
Stopping Epivir HBV may allow hepatitis B viral replication to increase, potentially triggering severe inflammation and worsening liver function.
Possible signs of hepatic decompensation include:
These symptoms require immediate medical evaluation because they may indicate serious liver complications.
If you have advanced liver disease, your healthcare provider may recommend particularly close monitoring during treatment and after any changes to your medication.
Seek emergency medical attention if you develop confusion, severe abdominal swelling, significant bleeding, or other symptoms suggesting liver failure.
If you are pregnant, planning to become pregnant, or think you may be pregnant, tell your healthcare provider before taking Epivir HBV.
Epivir HBV contains lamivudine, which can cross the placenta and reach the developing baby.
Although available human pregnancy data for lamivudine have not shown an increased overall risk of birth defects, information specifically evaluating the hepatitis B formulation remains limited.
Your healthcare provider will consider the potential benefits of treatment and any possible risks before recommending Epivir HBV during pregnancy.
Maintaining appropriate control of hepatitis B is important because active hepatitis B infection may affect your liver health and can potentially be transmitted to your baby.
Depending on your HBV DNA levels and other medical factors, your healthcare provider may recommend a different antiviral medication with more established use during pregnancy.
For example, tenofovir disoproxil fumarate is commonly preferred when antiviral treatment is needed during pregnancy to reduce hepatitis B transmission risk.
If you become pregnant while taking Epivir HBV, contact your healthcare provider promptly.
Do not stop taking Epivir HBV without medical advice, because interrupting treatment may cause hepatitis B to become more active and increase your risk of liver complications.
Your healthcare provider can determine the safest treatment plan and recommend appropriate monitoring throughout pregnancy.Â
If you are breastfeeding or planning to breastfeed, speak with your healthcare provider before taking Epivir HBV.
Unlike what was previously believed, lamivudine is known to pass into human breast milk.
The amount of medication that reaches a nursing infant depends on several factors, including the maternal dosage and the amount of milk consumed.
Although lamivudine exposure through breast milk is generally low, information about the effects of Epivir HBV on breastfed infants remains limited.
Your healthcare provider will consider the benefits of breastfeeding, the importance of hepatitis B treatment for your health, and any potential risks to your baby.
Hepatitis B infection itself does not usually prevent breastfeeding when the infant receives appropriate hepatitis B vaccination and other recommended preventive care.
However, if you also have HIV, additional considerations apply because HIV can be transmitted through breast milk. Your healthcare team should provide guidance based on your viral suppression, treatment, and current recommendations.
Do not stop your hepatitis B medication or breastfeeding without discussing your individual circumstances with your healthcare provider.
Lamivudine is primarily removed from your body through the kidneys.
If you have reduced kidney function, the medication may remain in your bloodstream longer than expected, potentially increasing the risk of side effects.
Tell your healthcare provider if you have kidney disease, reduced kidney function, or a history of kidney problems.
Your healthcare provider may recommend kidney function tests before starting treatment and periodically afterward.
If your kidney function is significantly reduced, your Epivir HBV dosage may need to be adjusted.
Do not change your dosage without medical advice.
Regular follow-up appointments and laboratory tests are important while taking Epivir HBV.
Your healthcare provider will monitor how effectively the medication suppresses hepatitis B and whether you are developing any treatment-related complications.
These tests may include HBV DNA testing, liver function tests, kidney function tests, and hepatitis B blood markers.
Monitoring is also important for detecting antiviral resistance, particularly if your viral load begins increasing after previously responding to treatment.
If Epivir HBV is discontinued, your healthcare provider should continue monitoring your liver function for at least several months because hepatitis B may become more active after treatment stops.
Contact your healthcare provider if you experience unusual fatigue, persistent nausea, abdominal pain, dark urine, jaundice, or other symptoms that may indicate liver problems.
You should also seek medical advice if you become pregnant, plan to breastfeed, develop kidney problems, or start taking new medications that may interact with lamivudine.
Seek emergency medical attention immediately if you develop severe breathing difficulties, symptoms of lactic acidosis, significant confusion, severe weakness, or signs of acute liver failure.
Always take Epivir HBV exactly as prescribed, attend regular follow-up appointments, and avoid stopping treatment without medical supervision.
Epivir HBV can help control chronic hepatitis B, but careful monitoring is essential to reduce the risk of liver complications, antiviral resistance, and serious medication-related side effects.
It is generally recommended to avoid drinking alcohol while taking Epivir HBV, particularly if you have chronic hepatitis B or existing liver damage. Epivir HBV is an antiviral medication used to treat chronic hepatitis B virus (HBV) infection. It works by reducing the amount of hepatitis B virus in your body, helping decrease liver inflammation and protect your liver from further damage. Chronic hepatitis B can cause ongoing inflammation in your liver, even when you do not experience noticeable symptoms. Drinking alcohol may increase this inflammation and contribute to additional liver damage. Over time, excessive alcohol consumption can increase the risk of liver scarring (fibrosis), cirrhosis, and liver failure. People living with chronic hepatitis B may be particularly vulnerable because their liver is already affected by a viral infection. Although alcohol is not known to cause a major direct interaction with lamivudine, drinking can place additional strain on your liver and may interfere with efforts to protect your long-term liver health. If you regularly consume alcohol, tell your healthcare provider how much and how often you drink. They can assess your liver function, explain your individual risks, and recommend appropriate precautions. Your healthcare provider may recommend avoiding alcohol completely, especially if you have elevated liver enzymes, cirrhosis, or other signs of liver damage. Avoiding alcohol is generally the safest approach for people with chronic hepatitis B. Continue taking Epivir HBV exactly as prescribed and attend regular appointments to monitor your liver health.
Yes, Epivir HBV may interact with certain medications, potentially affecting how well your treatment works or increasing your risk of side effects. Epivir HBV contains lamivudine, a nucleoside analogue antiviral medication that helps prevent hepatitis B from multiplying. Although lamivudine has fewer drug interactions than some other antiviral medications, certain combinations may affect its absorption, elimination, or effectiveness. For example, medications containing sorbitol, a sugar alcohol commonly found in certain liquid medicines, may reduce the amount of lamivudine absorbed into your bloodstream. This could potentially make treatment less effective. The antibiotic trimethoprim, which is often combined with sulfamethoxazole, may increase lamivudine exposure by reducing its elimination through the kidneys. Your healthcare provider may need to consider this interaction, particularly if you have reduced kidney function. You should also tell your healthcare provider if you take other antiviral medications used to treat hepatitis B or HIV. Some of these products already contain lamivudine or related ingredients, and taking overlapping medications may be inappropriate. Epivir HBV should not be used alone to treat HIV infection. If you have both HIV and hepatitis B, your healthcare provider will recommend an antiretroviral treatment regimen that appropriately treats both infections. Before starting Epivir HBV, provide your healthcare provider or pharmacist with a complete list of your medications, including prescription drugs, over-the-counter products, vitamins, herbal supplements, and natural health products. Do not start, stop, or change another medication without checking whether it can be used safely with Epivir HBV. If you experience unusual side effects or notice changes in your hepatitis B laboratory results, contact your healthcare provider for further evaluation.
The length of Epivir HBV treatment varies depending on your hepatitis B infection, liver health, viral load, and response to antiviral therapy. Chronic hepatitis B is a long-term viral infection that can cause ongoing liver inflammation and damage, even when you do not experience noticeable symptoms. Epivir HBV works by reducing hepatitis B viral replication, helping lower the amount of virus in your blood and protect your liver from further damage. However, Epivir HBV does not cure hepatitis B, and the virus may remain in your liver even when your blood tests show improvement. Some people may need antiviral treatment for several years, while others may require ongoing or lifelong treatment to maintain viral suppression. Your healthcare provider will determine how long you should continue taking Epivir HBV based on several factors, including your HBV DNA levels, liver enzyme results, hepatitis B blood markers, and whether you have cirrhosis or other liver complications. Regular blood tests are important for monitoring treatment effectiveness and detecting signs that hepatitis B is developing resistance to lamivudine. If the medication becomes less effective, your healthcare provider may recommend switching to another antiviral treatment. Do not stop taking Epivir HBV without medical supervision, even if you feel healthy or your laboratory results improve. Stopping treatment may allow hepatitis B to become active again, potentially causing a serious flare-up of liver inflammation. If treatment is discontinued, your healthcare provider will usually recommend close monitoring of your liver function and viral load for several months afterward. Maintaining regular medical appointments and following your prescribed treatment plan can help support long-term liver health.
Yes, Epivir HBV may be prescribed to treat chronic hepatitis B infection in children aged 2 to 17 years, provided their healthcare provider determines that the medication is appropriate. Chronic hepatitis B can affect children as well as adults. Although many children with hepatitis B experience few or no symptoms, the infection can cause ongoing liver inflammation and may increase the risk of liver complications later in life. Epivir HBV contains lamivudine, an antiviral medication that helps prevent hepatitis B from multiplying inside liver cells. By reducing viral replication, the medication may help lower HBV DNA levels, improve liver enzyme results, and decrease ongoing liver inflammation. The recommended pediatric dosage is based on the child’s body weight. According to U.S. prescribing information, the usual dose for children aged 2 to 17 years is 3 mg per kilogram of body weight once daily, up to a maximum of 100 mg per day. Epivir HBV is available as an oral tablet and an oral solution. The oral solution is generally recommended for children who require a dose below 100 mg or who have difficulty swallowing tablets. Your child’s healthcare provider will determine the appropriate dosage based on their weight, kidney function, liver health, and overall medical condition. Children receiving Epivir HBV require regular follow-up appointments and laboratory tests to monitor their viral load, liver function, and response to treatment. Long-term lamivudine use may lead to hepatitis B drug resistance, so your child’s healthcare provider will also consider whether another antiviral medication would be more appropriate. Do not change your child’s dosage or stop treatment without medical advice. Epivir HBV should only be used in children under the supervision of a healthcare provider experienced in managing pediatric hepatitis B. Following the prescribed dosage and attending regular medical appointments can help control the infection while reducing the risk of complications.
| Generic name: | Lamivudine |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 100mg |
| Quantities Available: | 90 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Epivir HBV (lamivudine) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Epivir HBV is commonly prescribed in a dosage of 100 mg once daily for adults. For a 90-day supply, this means you would order 90 tablets (90 days x 1 tablet per day).
Yes, we sell lamivudine on our website. You can enjoy low prices when you order through us. To purchase lamivudine, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication safely and appropriately. You can submit your prescription by mailing it to us, faxing it, or uploading it through your online account.
Yes, we ship Epivir HBV (lamivudine) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Epivir HBV (Lamivudine). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Epivir HBV (Lamivudine).
REVIEWS